

Opioid-Induced Constipation Therapeutic and Overview Pipeline Review H2

Opioid-Induced Constipation Treatment Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Opioid-Induced Constipation](#) (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619262-opioid-induced-constipation-oic-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

- The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects
- The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Opioid-Induced Constipation (OIC) Overview 7

Therapeutics Development 8

Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 8

Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 9

Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 10

Opioid-Induced Constipation (OIC) - Therapeutics under Investigation by Universities/Institutes 11

Opioid-Induced Constipation (OIC) - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Opioid-Induced Constipation (OIC) - Products under Development by Companies 15

Opioid-Induced Constipation (OIC) - Products under Investigation by Universities/Institutes 16

Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 17

Develco Pharma Schweiz AG 17

Ironwood Pharmaceuticals, Inc. 18

Shionogi & Co., Ltd. 19

Sucampo Pharmaceuticals, Inc. 20

Synergy Pharmaceuticals, Inc. 21

Theravance Biopharma, Inc. 22

Valeant Pharmaceuticals International, Inc. 23

Opioid-Induced Constipation (OIC) - Therapeutics Assessment 24

Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(axelopran sulfate + oxycodone hydrochloride) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
axelopran sulfate - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dolcanatide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
linaclotide - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lubiprostone - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
methylnaltrexone bromide - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
methylnaltrexone bromide - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
naldemedine tosylate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
naloxone hydrochloride PR - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62

Access Report @ <https://www.wiseguyreports.com/reports/619262-opioid-induced-constipation-oic-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.